A Meeting of Minds

Sometimes a partnership is the best way to take an idea to the next level. Merial regularly joins forces with leaders and thinkers in the industry and beyond—whatever it takes to move great ideas forward and into useful real-world solutions for our customers.

Our Key Areas of interest

Biologicals

  • Vaccine technologies, including: novel vectors and adjuvants; delivery mechanisms; and production and preservation methods
  • Bio-therapeutics for chronic diseases in pets
  • Biological or therapeutic treatments that enhance the productivity, health, and wellbeing of farm animals
  • Infectious disease of pets or farm animals
  • Diseases of public health or zoonotic concern

Pharmaceuticals

  • Molecular and active compound targets against internal and external parasites of pets or farm animals
  • Novel technologies for oral, topical, and injectable drug delivery, including flavor formulations, long-acting technologies, and device design
  • Infectious and inflammatory conditions in pets, especially skin, urinary, respiratory, and pain-related

SUCCESSFUL COLLABORATIONS

Some of our most important work has resulted from partnering with others outside Merial, including universities and research institutes, governments, and both established and start-up companies in biotech and human health. Here are some highlights.

Read more
Read more

A Novel Way to Fight Canine Cancer

In dogs, oral melanoma tumors can spread aggressively. Merial's innovative collaborations with Memorial Sloan Kettering Cancer Center (in clinical discovery) and biotech Vical (for core technology) led to a medical first: a vaccine that activates the immune system against cancer. We also partnered with Bioject Medical Technologies on the injection device, and the USDA's Center for Veterinary Biologics to help bring this cancer-fighting vaccine to market.

Read more
Read more

The Origins of Ivermectin

In the 1970s we partnered with researchers at the Kitasato Institute in Japan, who had isolated a compound with powerful anti-parasitic properties. This collaboration led to ivermectin, a drug effective against a wide range of parasites in many animals. It became the basis of many of our most successful products—including HEARTGARD® for cats and dogs and IVOMEC® for farm animals—and an industry blockbuster.

Read more
Read more

Partnering for Public Health Worldwide

Merial's leadership in fighting foot-and-mouth disease (FMD) dates back decades, and in that time we've learned that partnering on localized vaccine research and production is key to controlling this virulent virus. Examples include the Botswana Vaccine Institute, established in 1978 and now one of Africa's largest vaccine-producing labs, as well as our more recent 2013 partnership to establish the Special Vaccine Company of South Korea.

Read more
Read more

Demonstrating unique technologies

The development and launch of Merial's VAXXITEK® IBD, which has been used to dose over 59 billion birds since 2006, resulted from close collaboration with key university specialists and client veterinarians. Their participation allowed us to demonstrate the tangible benefits of the vaccine's unique enabling technology—compiling evidence critical to the product's swift rise and ongoing success.

Read more
Read more